UCB Signs a Definitive Agreement to Acquire Zogenix for ~$1.9B

Share this


UCB Signs a Definitive Agreement to Acquire Zogenix for ~$1.9B


  • UCB will acquire all outstanding shares of Zogenix for $26.00/share in cash & milestone-based CVR of $2.00/share upon achievement of EU approval of Fintepla for LGS by Dec 31, 2023 making a total value of $1.9B representing a premium of 72% to avg. closing stock price of Zogenix. The transaction is expected to close at the end of Q2’22
  • The acquisition will expands & builds upon UCB's role & adds Fintepla to UCB's existing product line to addres unmet needs of people living with specific or rare forms of epilepsy
  • Fintepla has been approved in the US & EU and is under regulatory review in Japan for the treatment of seizures associated with Dravet syndrome in patients aged ≥2yrs.

Ref: Zogenix | Image: Trading View

Click here to­ read the full press release 


Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions